Assenagon Asset Management S.A. bought a new position in Indivior PLC (NASDAQ:INDV - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,540,928 shares of the company's stock, valued at approximately $63,224,000. Assenagon Asset Management S.A. owned about 1.26% of Indivior at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the company. Quarry LP bought a new position in shares of Indivior in the third quarter valued at approximately $26,000. Raymond James Financial Inc. bought a new position in Indivior during the second quarter valued at about $26,000. Salomon & Ludwin LLC acquired a new position in Indivior during the fourth quarter worth about $30,000. Caitong International Asset Management Co. Ltd raised its position in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company's stock worth $39,000 after acquiring an additional 460 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its holdings in Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company's stock valued at $46,000 after acquiring an additional 1,076 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company's stock.
Indivior Price Performance
Shares of NASDAQ:INDV opened at $38.82 on Friday. The stock has a market capitalization of $4.58 billion, a price-to-earnings ratio of 13.91 and a beta of 0.86. The business's fifty day moving average price is $39.28 and its two-hundred day moving average price is $35.64. Indivior PLC has a fifty-two week low of $21.83 and a fifty-two week high of $42.81.
Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The firm had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. Research analysts expect that Indivior PLC will post 3.66 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Ryan Preblick sold 36,000 shares of the business's stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company's stock, valued at $10,735,112.70. The trade was a 11.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson purchased 1,500 shares of Indivior stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $36.28 per share, for a total transaction of $54,420.00. Following the completion of the transaction, the chief accounting officer directly owned 26,138 shares in the company, valued at $948,286.64. The trade was a 6.09% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.74% of the company's stock.
Analyst Ratings Changes
Several brokerages have recently commented on INDV. Barclays reduced their target price on Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Wednesday. Zacks Research downgraded Indivior from a "strong-buy" rating to a "hold" rating in a report on Monday, June 29th. Weiss Ratings raised shares of Indivior from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, July 24th. Finally, Craig Hallum restated a "buy" rating and set a $53.00 price target on shares of Indivior in a report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.17.
Read Our Latest Analysis on Indivior
Key Stories Impacting Indivior
Here are the key news stories impacting Indivior this week:
- Positive Sentiment: HC Wainwright raised its Indivior earnings forecasts across 2026–2030. The firm lifted its 2026 EPS estimate to $3.66 from $3.08, raised 2027 EPS to $3.83 from $3.34, and increased 2028–2030 estimates to $3.99, $4.22 and $4.46, respectively. Its quarterly estimates also rose to $0.93 for Q3 2026 and $1.07 for Q4, signaling improved expectations for the company’s operating performance. Indivior analyst estimates
- Positive Sentiment: An insider purchased additional shares. Chief Accounting Officer Woodrow Anderson bought 1,500 shares at an average price of $36.28, increasing his direct holdings by 6.09%. Insider buying can be viewed as a modest vote of confidence in the stock’s valuation and outlook. Insider Buying: Indivior CAO Acquires 1,500 Shares
- Neutral Sentiment: Analyst sentiment remains favorable but not uniformly bullish. Indivior has a consensus “Moderate Buy” rating and an average price target of $45.17, while individual recommendations include a $53.00 buy target from Craig Hallum and a reduced—but still “overweight”—$43.00 target from Barclays. Indivior receives Moderate Buy rating
- Negative Sentiment: A law firm is investigating the proposed Supernus acquisition. Kahn Swick & Foti is reviewing whether the transaction’s price and sale process adequately protect Supernus shareholders. Under the proposed deal, Supernus investors would receive 1.5401 Indivior shares per Supernus share. The investigation may add legal and execution uncertainty to the transaction and could raise concerns about potential share issuance and dilution for Indivior investors. Supernus Pharmaceuticals investor alert
Indivior Profile
(
Free Report)
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Featured Articles
Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.